ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This trial is testing a combination of four drugs — including two targeted drugs that attack a specific cancer gene mutation (BCR-ABL) and an immunotherapy drug — for people with a type of aggressive leukemia called BCR-ABL positive acute lymphoblastic leukemia (ALL) or a blast crisis phase of chronic myeloid leukemia (CML). **You may be eligible if...** - You have been diagnosed with BCR-ABL positive acute leukemia (a type that has the Philadelphia chromosome mutation) - You are not suitable for, or do not want, standard intensive chemotherapy (for the dose-finding phase) - You are 18 years or older (for the dose expansion phase) - You have cancer cells that are CD19-positive **You may NOT be eligible if...** - You have active, serious infections - You have a history of severe allergic reactions to the drugs used - You have uncontrolled heart disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.